TB 403

Drug Profile

TB 403

Alternative Names: Anti-placental growth factor monoclonal antibody; Anti-PlGF; Anti-PlGF monoclonal antibody; R-7334; RG 7334; RO-5323441; TB-403; THR-317; αPlGF

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioInvent International; ThromboGenics
  • Developer BioInvent International; Oncurious; Roche; ThromboGenics
  • Class Anti-inflammatories; Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Placenta growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Medulloblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic macular oedema
  • Phase I/II Medulloblastoma
  • No development reported Age-related macular degeneration; Diabetic retinopathy; Glioblastoma; Hepatocellular carcinoma; Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetic-retinopathy in Belgium (Ophthalmic)
  • 17 Jan 2017 THR 317 receives Orphan Drug status for Medulloblastoma in European Union
  • 16 Jan 2017 EMA Committee for Orphan Medicinal Products issues positive opinion on orphan drug designation for THR 317 in the European Union for Medulloblastoma before January 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top